Fagron

Personalized medicine is the central commercial focus of Fagron, which develops pharmaceutical compounding concepts, formulations, ingredients, equipment, and supporting scientific resources for pharmacies and healthcare professionals. Its portfolio covers active pharmaceutical ingredients, excipients, dosage form vehicles, packaging, and compounding equipment for use across the preparation process. Branded lines include Pentravan transdermal bases, SyrSpend oral suspending vehicles, DiluCap capsule excipients, and DiluTab systems for pharmacy-scale tablet compounding. These products address formulation requirements such as solubility, moisture protection, disintegration, controlled release, and patient-friendly dosage forms.

The group combines research and development expertise with a global operating footprint in EMEA, North America, and Latin America. It reports around 5,000 employees, operations in more than 30 countries, and approximately 70 offices and compounding facilities. More than 400 pharmacists contribute to the development of its compounding brands and scientific work. Beyond materials and equipment, the business maintains a formulary initiative linking customized formulas with prescribing indications and operates an academy for pharmaceutical compounding and medical scientific training. Its activities also extend to pharmacogenetics and diagnostic molecular analysis through Fagron Genomics, reflecting a broader role in tools and knowledge used to individualize treatment.